Out of the 33 analysts that have coverage on Zydus Lifesciences, 17 of them have a "buy" rating, 10 say "hold", while six of them have a "sell" rating on the stock.
from Video News in CNBCTV18, Video Latest News, Video News https://ift.tt/QVWf30O
Zydus Life's US revenue may fall 5% in FY26 but Nomura sees a 15% upside
शुक्रवार, जनवरी 10, 2025
0
